Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes.

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes. / Rauch, T; Graefe-Mody, U; Deacon, Carolyn F.; Ring, A; Holst, Jens Juul; Woerle, H-J; Dugi, KA; Heise, T.

In: Diabetes Therapy, Vol. 3, No. 1, 2012, p. 10.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Rauch, T, Graefe-Mody, U, Deacon, CF, Ring, A, Holst, JJ, Woerle, H-J, Dugi, KA & Heise, T 2012, 'Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes.', Diabetes Therapy, vol. 3, no. 1, pp. 10. https://doi.org/10.1007/s13300-012-0010-y

APA

Rauch, T., Graefe-Mody, U., Deacon, C. F., Ring, A., Holst, J. J., Woerle, H-J., ... Heise, T. (2012). Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes. Diabetes Therapy, 3(1), 10. https://doi.org/10.1007/s13300-012-0010-y

Vancouver

Rauch T, Graefe-Mody U, Deacon CF, Ring A, Holst JJ, Woerle H-J et al. Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes. Diabetes Therapy. 2012;3(1):10. https://doi.org/10.1007/s13300-012-0010-y

Author

Rauch, T ; Graefe-Mody, U ; Deacon, Carolyn F. ; Ring, A ; Holst, Jens Juul ; Woerle, H-J ; Dugi, KA ; Heise, T. / Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes. In: Diabetes Therapy. 2012 ; Vol. 3, No. 1. pp. 10.

Bibtex

@article{44d67a0aab4045afbd3c7f0d7390df40,
title = "Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes.",
author = "T Rauch and U Graefe-Mody and Deacon, {Carolyn F.} and A Ring and Holst, {Jens Juul} and H-J Woerle and KA Dugi and T Heise",
year = "2012",
doi = "10.1007/s13300-012-0010-y",
language = "English",
volume = "3",
pages = "10",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes.

AU - Rauch, T

AU - Graefe-Mody, U

AU - Deacon, Carolyn F.

AU - Ring, A

AU - Holst, Jens Juul

AU - Woerle, H-J

AU - Dugi, KA

AU - Heise, T

PY - 2012

Y1 - 2012

U2 - 10.1007/s13300-012-0010-y

DO - 10.1007/s13300-012-0010-y

M3 - Journal article

VL - 3

SP - 10

JO - Diabetes Therapy

JF - Diabetes Therapy

SN - 1869-6953

IS - 1

ER -

ID: 40389687